<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22202" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Genital Warts</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sajjad</surname>
            <given-names>Hussain</given-names>
          </name>
          <aff>RMU and Allied Hospitals</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kumar</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>VA Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hussain Sajjad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Kumar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22202.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Genital warts (condyloma acuminatum) are a sexually transmitted infection caused by the human papillomavirus (HPV) types 6 and 11. These are spread by skin-to-skin contact, usually during sex. These present in clusters or separately and can be found in the genital or anal area. This activity describes the evaluation and management of genital warts and explains the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the etiology of genital warts.</p></list-item><list-item><p>Review the importance of biopsy in the evaluation of genital warts.</p></list-item><list-item><p>Explain the use of physically destructive therapies and topical agents in the management of genital warts.</p></list-item><list-item><p>Summarize the importance of collaboration and communication among the interprofessional team members to educate patients on the importance of the HPV vaccine, which will enhance the delivery of care for patients with genital warts.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22202&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22202">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22202.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Genital warts (condyloma acuminatum) are the clinical manifestations of a&#x000a0;sexually transmitted&#x000a0;infection caused by some types of human papillomavirus (HPV).<xref ref-type="bibr" rid="article-22202.r1">[1]</xref></p>
        <p>Warts are a recognized symptom of genital HPV infections. About 90% of those exposed who contract HPV will not develop genital warts. Only about&#x000a0;10% who are infected will transmit the virus. HPV types 6 and 11 cause&#x000a0;genital warts. There are over 100 different known types of HPV viruses.&#x000a0;HPV is&#x000a0;spread through direct skin-to-skin contact with an infected individual, usually during sex. While some&#x000a0;types of HPV cause cervical and anal cancer, these are not the same viral types&#x000a0;that cause genital warts. It is&#x000a0;possible to be infected with different types of&#x000a0;HPV at the same time.<xref ref-type="bibr" rid="article-22202.r1">[1]</xref></p>
      </sec>
      <sec id="article-22202.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>HPV is transmitted&#x000a0;primarily through penetrative sex. While HPV&#x000a0;also&#x000a0;can be transmitted via non-penetrative sexual activity, it is less common.<xref ref-type="bibr" rid="article-22202.r1">[1]</xref><xref ref-type="bibr" rid="article-22202.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>There is conflicting evidence about the effect of condoms on prevention.</p>
          </list-item>
          <list-item>
            <p>About 30% of genital warts will disappear within four months of their initial appearance.</p>
          </list-item>
          <list-item>
            <p>Most genital warts will recur within three months of completion of initial therapy, even if therapy was followed correctly.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Recurrence rates depend on the patient's general health and immune status, previous HPV vaccinations, specific HPV strain, number of inoculations (sexual frequency with an infected partner), use of condoms, and the viral load.</p>
          </list-item>
          <list-item>
            <p>Smoking increases the risk of getting genital warts.</p>
          </list-item>
          <list-item>
            <p>Approximately three out of four unaffected partners of patients with warts develop them within eight months of contact.</p>
          </list-item>
          <list-item>
            <p>Although 90% of HPV infections are cleared within two years of infection, it is possible for a latency&#x000a0;period to occur, with the first occurrence or a recurrence happening months or even years later.</p>
          </list-item>
          <list-item>
            <p>Latent HPV is transmissible, and if an individual has unprotected sex with an infected partner, there is a 70% chance they will become infected.</p>
          </list-item>
          <list-item>
            <p>In individuals with a prior HPV infection, the appearance of new warts may be either&#x000a0;from a new exposure or a recurrence.</p>
          </list-item>
          <list-item>
            <p>Anal or genital warts may be transmitted during birth and may be an indicator of sexual abuse.</p>
          </list-item>
          <list-item>
            <p>Genital warts may sometimes result from autoinoculation by warts elsewhere on the body, such as from the hands.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22202.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Genital HPV infections have an estimated prevalence of 10% to 20%, with clinical manifestations in 1%. The incidence of HPV infection has been increasing. About 80% of those infected are between the ages of 17 and 33 years, with the peak age group being 20 to 24.&#x000a0; It has been estimated that 2.9% of the US male population will have genital HPV DNA.&#x000a0;</p>
        <p>Although treatments can remove warts, they do not remove HPV. Warts may sometimes&#x000a0;spontaneously regress. Traditional theories postulate that the virus remains in the body for a lifetime. However, it is now believed that&#x000a0;the virus may be either cleared or suppressed to levels below what polymerase chain reaction (PCR) tests can measure.</p>
        <p>HPV infection appears to be the cause of most cases of anal cancer (about 90%) and virtually all&#x000a0;cases of&#x000a0;cervical cancer in women, with HPV type 16 accounting for about 50% of these.&#x000a0; (Cervical cancer is the fourth most common cancer in women.) Some vulvar cancers have been linked to HPV infections (29% to 43%),&#x000a0;while vaginal cancer is associated with HPV infections about 70% of the time (HPV Types 16 and 18).<xref ref-type="bibr" rid="article-22202.r3">[3]</xref></p>
        <p>In men,&#x000a0;Bowen disease of the penis and about 35% to 40% of all penile cancers are associated with HPV infections.<xref ref-type="bibr" rid="article-22202.r4">[4]</xref></p>
        <p>Risk factors for HPV persistence include age, smoking, immunosuppression, and simultaneous infection with multiple HPV types.<xref ref-type="bibr" rid="article-22202.r5">[5]</xref></p>
        <p>
<bold>HPV Vaccinations</bold>
</p>
        <p>An HPV vaccination is available.&#x000a0;</p>
        <p>For previously unvaccinated adults, the CDC suggests vaccinations for those 27 to 45 years of age.&#x000a0;</p>
        <p>For adolescents, the CDC suggests the vaccine be given at ages 11 or 12 years, but may be started as early as 9.&#x000a0;</p>
      </sec>
      <sec id="article-22202.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Genital warts are typically diagnosed visually, with confirmatory biopsy generally&#x000a0;unnecessary.&#x000a0;These exophytic lesions form due to enlargement of the dermal papillae and are lined by hyperplastic squamous epithelium that shows koilocytes, which are squamous epithelial cells characterized by an acentric, hyperchromatic nucleus displaced by a large perinuclear vacuole.<xref ref-type="bibr" rid="article-22202.r6">[6]</xref></p>
      </sec>
      <sec id="article-22202.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Genital warts may occur separately or in clusters. They may be found in the anal or genital area, including the penile shaft, scrotum, vagina, or labia majora. They can also be found on internal surfaces of the vagina and&#x000a0;the anus. They can be small (5 mm or less in diameter) or spread into large masses in the genital or anal area. Their color is variable but tends to be skin-colored or darker, and they may occasionally&#x000a0;bleed spontaneously.</p>
        <p>Sometimes warts may cause itching, redness, or discomfort. An outbreak of genital warts may also cause psychological distress. In most cases, the only identifiable&#x000a0;symptoms of an&#x000a0;HPV infection are warts.</p>
      </sec>
      <sec id="article-22202.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of genital warts is usually made visually, although a biopsy may be necessary&#x000a0;for&#x000a0;confirmation. Small warts may sometimes be confused with molluscum contagiosum. Genital warts typically rise above the skin surface, have parakeratosis, and demonstrate&#x000a0;nuclear changes typical of HPV infections (nuclear enlargement with perinuclear clearing). Because genital warts are caused by low-risk HPV types, DNA tests&#x000a0;should not be used for diagnosis&#x000a0;or in low-risk HPV infections.</p>
        <p>Some practitioners use an acetic acid solution to help identify small warts and affected skin areas, but this practice is controversial.&#x000a0;&#x000a0;</p>
        <p>A biopsy is recommended if there is uncertainty about the diagnosis or if the patient is immunocompromised. Pigmented and ulcerated lesions should also be considered for biopsy.</p>
        <p>Cystoscopy should be considered in patients where the glans is involved, the patient has lower urinary tract symptoms, or there are significant urethral symptoms. In patients who have no symptoms, some experts have suggested waiting until any glans lesions have healed to avoid possible&#x000a0;transfer of the HPV virus into the urethra.<xref ref-type="bibr" rid="article-22202.r7">[7]</xref><xref ref-type="bibr" rid="article-22202.r8">[8]</xref></p>
      </sec>
      <sec id="article-22202.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is no cure for HPV. Removing visible warts does not necessarily reduce the transmission of the underlying HPV infection.<xref ref-type="bibr" rid="article-22202.r9">[9]</xref><xref ref-type="bibr" rid="article-22202.r10">[10]</xref><xref ref-type="bibr" rid="article-22202.r11">[11]</xref> About 80% of individuals with HPV will clear the infection spontaneously within 18 to 24 months.</p>
        <p>Treatment varies depending on the number, size, and&#x000a0;location of warts. Treatment can cause permanent depigmentation, itching, pain, and scarring.</p>
        <p>Urethral meatus warts are best treated with surgery to minimize long-term complications.</p>
        <p>The American Urological Association does not recommend treating sub-clinical (invisible) lesions.</p>
        <p>Treatments are either&#x000a0;ablative (vaporization, resection, coagulation, or excision) or involve the use of topical agents. Physically ablative treatments are more effective at wart removal; but in many cases, topical agents are preferred by patients as initial therapy, especially for smaller lesions.</p>
        <p>
<bold>Topical Agents</bold>
</p>
        <p>Topical agents may be very effective, are self-applied by patients, and are less traumatic than surgical intervention. However, patient compliance is spotty and recurrences are common.</p>
        <p><bold>Podophyllotoxin</bold> solution 0.15% to 0.5% in a gel or cream can be applied to the affected area and is not washed off. Podofilox (an anti-mitotic drug) appears to be safer than podophyllin.<xref ref-type="bibr" rid="article-22202.r12">[12]</xref>&#x000a0;It works by binding microtubular subunits.<xref ref-type="bibr" rid="article-22202.r13">[13]</xref>&#x000a0;The gel form is easier for patients to apply than the liquid with equal efficacy.<xref ref-type="bibr" rid="article-22202.r14">[14]</xref>&#x000a0;The recommended application schedule (apply BID for three days followed by four days off, then repeat) can be confusing for some patients. Side effects include localized burning, itching, pain, and inflammation. Should not be used in pregnancy. The original precursor topical therapy, podophyllin, is no longer recommended by the CDC due to its high level of mutagens.<xref ref-type="bibr" rid="article-22202.r15">[15]</xref></p>
        <p><bold>Imiquimod</bold> is a topical immune response cream applied to the affected area&#x000a0;but may cause fungal infections and flu-like symptoms. Imiquimod is an immune enhancer and increases cytokines (such as tumor necrosis factor-alpha (TNF-a) and interferon alfa). This causes an enhanced cytotoxic immune reaction based on T cell-mediated response factors.<xref ref-type="bibr" rid="article-22202.r13">[13]</xref>&#x000a0;Wart recurrence rates are better than podophyllin-based therapies and it tends to cause non-scarring healing.<xref ref-type="bibr" rid="article-22202.r16">[16]</xref>&#x000a0;The recommended application schedule for imiquimod 5% cream is three times per week.<xref ref-type="bibr" rid="article-22202.r17">[17]</xref>&#x000a0;Usage of imiquimod 3.75% cream has been recommended as being equally effective while minimizing local side effects such as pain, burning, inflammation, itching, and erythema.<xref ref-type="bibr" rid="article-22202.r18">[18]</xref><xref ref-type="bibr" rid="article-22202.r19">[19]</xref><xref ref-type="bibr" rid="article-22202.r20">[20]</xref>&#x000a0;Usage may also be limited by cost as the medication is relatively expensive if not covered by insurance.</p>
        <p><bold>Sinecatechins</bold> are an ointment of catechins extracted from green tea that&#x000a0;appear to have a higher wart clearance rate&#x000a0;than podophyllotoxin and imiquimod while causing less local irritation, but clearance takes longer than with imiquimod. The overall wart clearance rate is reported as high as 57.2%.<xref ref-type="bibr" rid="article-22202.r21">[21]</xref>&#x000a0;</p>
        <p>Sinecatechins are available as a 15% ointment. The exact mechanism of action is unknown, but they have immuno-stimulatory, anti-proliferative and anti-tumor properties and appear to work by reducing HPV gene products E6 and E7.<xref ref-type="bibr" rid="article-22202.r22">[22]</xref>&#x000a0;Side effects include local redness, inflammation, and pain.</p>
        <p><bold>Isotretinoin</bold>&#x000a0;is a medication typically used for acne. It acts to reduce sebum, shrink sebaceous glands, provides an anti-inflammatory effect, and has anti-bacterial benefits. Isotretinoin has also shown significant efficacy when used as an adjunct to standard treatment of genital warts in immunocompromised patients, where the condyloma are extensive or if the lesions have proven resistant to initial therapy.<xref ref-type="bibr" rid="article-22202.r23">[23]</xref><xref ref-type="bibr" rid="article-22202.r24">[24]</xref><xref ref-type="bibr" rid="article-22202.r25">[25]</xref><xref ref-type="bibr" rid="article-22202.r26">[26]</xref>&#x000a0;The dosage is 0.5 to 1 mg/kg/day.&#x000a0; Topical therapy is continued during treatment. There are many potential side effects to isotretinoin therapy so it must be used cautiously. In particular, it can cause very severe birth defects and so should absolutely not be used in pregnancy. For women of childbearing age, this means two pregnancy tests initially and monthly while on medication. They must also use two separate forms of birth control. Side effects include dry skin, chapped lips, frequent nosebleeds, dry eyes, dry mouth, and severe sun sensitivity while on the medication.&#x000a0; There may also be night blindness, hair thinning, muscle aches, arthralgias, rashes, stomach problems, and higher cholesterol levels. Liver damage, urethritis, and hydrocephalus have been reported but are quite rare.<xref ref-type="bibr" rid="article-22202.r27">[27]</xref>&#x000a0;Side effects are typically dose-dependent. There are a few reported cases of severe depression and suicide associated with the use of isotretinoin as well as possibly exacerbation of inflammatory bowel disease. For these reasons, isotretinoin is only dosed in 30-day intervals and it should be used cautiously.<xref ref-type="bibr" rid="article-22202.r23">[23]</xref></p>
        <p><bold>Trichloroacetic acid</bold>&#x000a0;is not as effective as cryosurgery and should be avoided&#x000a0;on the vagina, cervix, or urinary meatus.<xref ref-type="bibr" rid="article-22202.r6">[6]</xref>&#x000a0;It tends to have a high recurrence rate and should be applied only by a healthcare provider due to potential injury to surrounding tissues.<xref ref-type="bibr" rid="article-22202.r28">[28]</xref></p>
        <p>Skin erosion and pain are most commonly reported with imiquimod and sinecatechins.</p>
        <p>
<bold>Physical (Surgical) Removal or Destruction</bold>
</p>
        <p>Direct surgical excision or physically destructive therapies are considered&#x000a0;more effective on keratinized warts, especially if they are larger in size.<xref ref-type="bibr" rid="article-22202.r6">[6]</xref></p>
        <p><bold>Simple surgical excision</bold> under local anesthesia is simple and direct but will leave a scar and requires a small surgical procedure.<xref ref-type="bibr" rid="article-22202.r9">[9]</xref></p>
        <p><bold>Liquid nitrogen cryosurgery ablation&#x000a0;</bold>is inexpensive, considered safe for use during pregnancy, and does not usually cause much scarring but requires cryosurgical equipment and training. It may require anesthesia due to pain and multiple treatments are often necessary.&#x000a0;</p>
        <p><bold>Electrocauterization</bold> is considered&#x000a0;effective but causes scarring and requires some&#x000a0;level of anesthesia.<xref ref-type="bibr" rid="article-22202.r6">[6]</xref></p>
        <p><bold>Laser vaporization</bold> has minimal bleeding but may be somewhat&#x000a0;less effective than other ablative techniques. It is typically used for extensive areas of genital wart involvement, is relatively expensive, and may cause a plume of virus-containing smoke.<xref ref-type="bibr" rid="article-22202.r29">[29]</xref><xref ref-type="bibr" rid="article-22202.r30">[30]</xref></p>
        <p><bold>Surgical&#x000a0;removal under general anesthesia</bold> may be necessary for more extensive lesions, intra-anal warts, or in children.&#x000a0;</p>
        <p><bold>Photodynamic therapy</bold> with a photosensitizing agent (such as aminolevulinic acid) has demonstrated efficacy in eliminating external warts. The aminolevulinic acid is applied topically or directly intralesionally. The photosensitizing agent is absorbed quickly into the most rapidly growing cells. Light exposure activates the aminolevulinic acid releasing free oxygen singlet radicals resulting in the destruction of the wart by direct oxidative injury.<xref ref-type="bibr" rid="article-22202.r31">[31]</xref><xref ref-type="bibr" rid="article-22202.r32">[32]</xref><xref ref-type="bibr" rid="article-22202.r33">[33]</xref><xref ref-type="bibr" rid="article-22202.r34">[34]</xref>&#x000a0;This technique is currently considered off-label.</p>
        <p>
<bold>Discontinued</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>5-fluorouracil (5-FU) 5% cream is no longer considered acceptable due to side effects.</p>
          </list-item>
          <list-item>
            <p>Interferon intralesional injections initially showed moderate efficacy with a complete response rate of 36% - 63% as monotherapy, but it has largely been supplanted by other treatments. Might still be considered for intractable cases as an adjunctive therapy.<xref ref-type="bibr" rid="article-22202.r18">[18]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Podophyllin, podofilox, and especially isotretinoin should be avoided during pregnancy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22202.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Condyloma lata or secondary syphilis</p>
          </list-item>
          <list-item>
            <p>Familial benign pemphigus</p>
          </list-item>
          <list-item>
            <p>Herpes simplex infection</p>
          </list-item>
          <list-item>
            <p>Benign nevi</p>
          </list-item>
          <list-item>
            <p>Vulvar neurofibromatosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22202.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>A large number of cases of genital warts fail to respond to treatment and often recur, especially with repeated infections from sexual contact or the long-incubation period of HPV. Verifying patient compliance with therapy, changing the therapeutic agent, and adding isotretinoin can help.&#x000a0;Morbidity associated with the disease is due to pruritus, bleeding, and the psychosocial burden of genital lesions, while mortality is due to its malignant transformation to squamous cell carcinoma.&#x000a0;</p>
        <p>Immunocompromised patients are likely to have more resistant lesions than the general population with more frequent recurrences. They are also more likely for their lesions to develop a malignant transformation into squamous cell carcinoma.<xref ref-type="bibr" rid="article-22202.r35">[35]</xref><xref ref-type="bibr" rid="article-22202.r36">[36]</xref>&#x000a0;In general, immunocompromised patients generally benefit from a combination of therapies, early addition of isotretinoin, a longer duration of treatment, and earlier implementation of surgery.<xref ref-type="bibr" rid="article-22202.r37">[37]</xref></p>
      </sec>
      <sec id="article-22202.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Local complications with&#x000a0;disfigurement are the most common complications of this disease. With untreated and advanced-stage disease, there is a risk of malignant transformation, which is the most feared complication. The current standard of care emphasizes treatment and primary prevention strategies, including vaccination, to prevent this devastating outcome.&#x000a0;</p>
      </sec>
      <sec id="article-22202.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Gardasil is a vaccine used to&#x000a0;protect&#x000a0;against human papillomavirus types 6, 11, 16, and 18. Types 16 and 18 cause an estimated 70% of cervical cancers, and 6 and 11 cause an estimated 90% of genital warts. The vaccine prevents the disease&#x000a0;but is not therapeutic. The vaccine must be given before&#x000a0;exposure to the virus type to be effective. The vaccine was&#x000a0;approved by the United States Food and Drug Administration (FDA) in 2006 for use in&#x000a0;children as early as nine years of age, primarily for its prophylactic activity against cervical cancer. Gardasil 9 was FDA approved in 2014 to protect against the four HPV strains covered by the first generation of Gardasil as well as five other HPV strains responsible for 20% of cervical cancers (HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58).<xref ref-type="bibr" rid="article-22202.r38">[38]</xref></p>
        <p>Vaccines are preventative and should not be considered therapeutic. Quadrivalent or 9-valent vaccines are recommended and generally&#x000a0;preferred over bivalent vaccines.</p>
        <p>According to the Advisory Committee for Immunization Practices (ACIP), routine HPV vaccination is recommended for women 9 to 26 years of age, but it has shown high efficacy up to age 45. The CDC advises that unvaccinated adults above 26 years to age 45 may be given the vaccine after discussion with their provider.&#x000a0;</p>
        <p>The ACIP recommends routine male HPV quadrivalent vaccinations at age 11-12.&#x000a0; If not previously given or incomplete (the vaccines are a three-dose series), the vaccine should be given up to age 21.&#x000a0; From ages 22 to 26, the vaccine is considered optional.&#x000a0; In other words, the optimal age for male HPV vaccination is 11 to 12 years, but it may be given up to age 45 years.&#x000a0;</p>
        <p>It remains to be seen if the more extensive use of vaccines can reduce the prevalence and penetration of HPV exposure, infections, and complications.</p>
      </sec>
      <sec id="article-22202.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Experimentally, a nitric acid/zinc complex solution for topical application has been successfully used on difficult to treat warts. The solution includes dilute nitric acid, zinc, copper, and organic acids. The application of this solution causes destruction and desiccation of the wart through a combination of denaturation and active protein coagulation actions. So far, it appears to be well tolerated and effective.<xref ref-type="bibr" rid="article-22202.r39">[39]</xref><xref ref-type="bibr" rid="article-22202.r40">[40]</xref></p>
        <p>The use of antivirals such as topical cidofovir also appears promising, but more study is needed before it can be safely utilized clinically.<xref ref-type="bibr" rid="article-22202.r41">[41]</xref><xref ref-type="bibr" rid="article-22202.r42">[42]</xref><xref ref-type="bibr" rid="article-22202.r43">[43]</xref><xref ref-type="bibr" rid="article-22202.r44">[44]</xref></p>
        <p>Curcumin, a derivative of turmeric, has shown efficacy against genital warts anecdotally, but more study is needed to determine its true safety and effectiveness.<xref ref-type="bibr" rid="article-22202.r45">[45]</xref></p>
      </sec>
      <sec id="article-22202.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Genital warts are very&#x000a0;common&#x000a0;in clinical practice. Because of the risk of cancer, there is now a vaccine available to prevent these warts. Healthcare workers, including nurse practitioners, physician&#x000a0;assistants, and primary care physicians, need to work in an interprofessional effort to educate patients about the importance of the HPV vaccine as it can prevent a variety of genital cancers. The ACIP recommends routine male HPV quadrivalent vaccinations at age 11-12. &#x000a0;If not previously given or incomplete (the vaccines are a three-dose series), the vaccine should be given up to age 21. From ages 22 to 26, the vaccine is considered optional. In other words, the optimal age for male HPV vaccination is 11 to 12 years, but it may be given up to age 26 years.</p>
      </sec>
      <sec id="article-22202.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22202&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22202">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/sexual-health/genital-warts/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22202">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22202/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22202">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22202.s16">
        <fig id="article-22202.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Genital Warts, Female <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genital__warts__female" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22202.s17">
        <fig id="article-22202.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Genital Warts, Male <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genital__warts__male" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22202.s18">
        <title>References</title>
        <ref id="article-22202.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sendagorta-Cud&#x000f3;s</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Burgos-Cibri&#x000e1;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Iglesias</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Genital infections due to the human papillomavirus.</article-title>
            <source>Enferm Infecc Microbiol Clin (Engl Ed)</source>
            <year>2019</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>324</fpage>
            <page-range>324-334</page-range>
            <pub-id pub-id-type="pmid">30853139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozaydin-Yavuz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bilgili</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Guducuoglu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yavuz</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Elibuyuk-Aksac</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karadag</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Determinants of high-risk human papillomavirus infection in anogenital warts.</article-title>
            <source>Postepy Dermatol Alergol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-81</page-range>
            <pub-id pub-id-type="pmid">30858783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lisboa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Azevedo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Azevedo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pista</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>High Prevalence of Human Papillomavirus on Anal and Oral Samples from Men and Women with External Anogenital Warts: The HERCOLES Study.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>99</volume>
            <issue>6</issue>
            <fpage>557</fpage>
            <page-range>557-563</page-range>
            <pub-id pub-id-type="pmid">30723872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stratton</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Culkin</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>A Contemporary Review of HPV and Penile Cancer.</article-title>
            <source>Oncology (Williston Park)</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>245</fpage>
            <page-range>245-9</page-range>
            <pub-id pub-id-type="pmid">26984219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sichero</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Giuliano</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Villa</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Human Papillomavirus and Genital Disease in Men: What We Have Learned from the HIM Study.</article-title>
            <source>Acta Cytol</source>
            <year>2019</year>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-117</page-range>
            <pub-id pub-id-type="pmid">30799416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Barankin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Hon</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Penile warts: an update on their evaluation and management.</article-title>
            <source>Drugs Context</source>
            <year>2018</year>
            <volume>7</volume>
            <fpage>212563</fpage>
            <pub-id pub-id-type="pmid">30622585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zayko</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Velilla</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Shurbaji</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Condyloma Acuminata Presenting as Isolated Papillary Lesions in the Prostatic Urethra.</article-title>
            <source>Am J Case Rep</source>
            <year>2018</year>
            <month>Dec</month>
            <day>22</day>
            <volume>19</volume>
            <fpage>1522</fpage>
            <page-range>1522-1525</page-range>
            <pub-id pub-id-type="pmid">30578409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iskander</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patrick</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mistry</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Intra urethral human papillomavirus related warts following urinary tract instrumentation.</article-title>
            <source>Urol J</source>
            <year>2014</year>
            <month>May</month>
            <day>06</day>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>1491</fpage>
            <pub-id pub-id-type="pmid">24807766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beutner</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Reitano</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Richwald</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Wiley</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts.</article-title>
            <source>Clin Infect Dis</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>796</fpage>
            <page-range>796-806</page-range>
            <pub-id pub-id-type="pmid">9798036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiley</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beutner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fife</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moscicki</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Fukumoto</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>External genital warts: diagnosis, treatment, and prevention.</article-title>
            <source>Clin Infect Dis</source>
            <year>2002</year>
            <month>Oct</month>
            <day>15</day>
            <volume>35</volume>
            <issue>Suppl 2</issue>
            <fpage>S210</fpage>
            <page-range>S210-24</page-range>
            <pub-id pub-id-type="pmid">12353208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Workowski</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bolan</surname>
                <given-names>GA</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention</collab>
            </person-group>
            <article-title>Sexually transmitted diseases treatment guidelines, 2015.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2015</year>
            <month>Jun</month>
            <day>05</day>
            <volume>64</volume>
            <issue>RR-03</issue>
            <fpage>1</fpage>
            <page-range>1-137</page-range>
            <pub-id pub-id-type="pmid">26042815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Meadows</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dor&#x000e9;</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Copas</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Haddow</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Lacey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soldan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tetlow</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gilson</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial).</article-title>
            <source>BMC Med Res Methodol</source>
            <year>2018</year>
            <month>Nov</month>
            <day>06</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <pub-id pub-id-type="pmid">30400777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Yen-Moore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tyring</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>An overview of sexually transmitted diseases. Part II.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>5 Pt 1</issue>
            <fpage>661</fpage>
            <page-range>661-77; quiz 678-80</page-range>
            <pub-id pub-id-type="pmid">10534627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyring</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cherry</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ramsdell</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Kotner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Vance</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Barnum</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dromgoole</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Killey</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Toter</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts.</article-title>
            <source>Arch Dermatol</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-8</page-range>
            <pub-id pub-id-type="pmid">9449907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petersen</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Weismann</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Quercetin and kaempherol: an argument against the use of podophyllin?</article-title>
            <source>Genitourin Med</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>71</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-3</page-range>
            <pub-id pub-id-type="pmid">7744421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Severson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arany</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tyring</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Human papillomavirus infections: epidemiology, pathogenesis, and therapy.</article-title>
            <source>J Cutan Med Surg</source>
            <year>2001</year>
            <season>Jan-Feb</season>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-60</page-range>
            <pub-id pub-id-type="pmid">11281434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gotovtseva</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Kapadia</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Smolensky</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lairson</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis.</article-title>
            <source>Sex Transm Dis</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>346</fpage>
            <page-range>346-51</page-range>
            <pub-id pub-id-type="pmid">18360317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czelusta</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arany</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tyring</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>A guide to immunotherapy of genital warts: focus on interferon and imiquimod.</article-title>
            <source>BioDrugs</source>
            <year>1999</year>
            <month>May</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>319</fpage>
            <page-range>319-32</page-range>
            <pub-id pub-id-type="pmid">18031142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The role of imiquimod 3.75% cream in the treatment of external genital warts.</article-title>
            <source>Skin Therapy Lett</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>5</fpage>
            <page-range>5-7</page-range>
            <pub-id pub-id-type="pmid">22491804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ault</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men.</article-title>
            <source>Cutis</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-82</page-range>
            <pub-id pub-id-type="pmid">26682290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tatti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Swinehart</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Thielert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tawfik</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mescheder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beutner</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial.</article-title>
            <source>Obstet Gynecol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>111</volume>
            <issue>6</issue>
            <fpage>1371</fpage>
            <page-range>1371-9</page-range>
            <pub-id pub-id-type="pmid">18515521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000f6;fer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tatti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lynde</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Skerlev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hercogov&#x000e1;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rotaru</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ballesteros</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Calzavara-Pinton</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sinecatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults.</article-title>
            <source>Int J STD AIDS</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>14</issue>
            <fpage>1433</fpage>
            <page-range>1433-1443</page-range>
            <pub-id pub-id-type="pmid">28566057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jha</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Sonthalia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ganguly</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Oral isotretinoin as an adjunctive treatment for recurrent genital warts.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>e35</fpage>
            <page-range>e35-e36</page-range>
            <pub-id pub-id-type="pmid">29332721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nickle</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>22</fpage>
            <page-range>22-34</page-range>
            <pub-id pub-id-type="pmid">24765227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yew</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Complete remission of recalcitrant genital warts with a combination approach of surgical debulking and oral isotretinoin in a patient with systemic lupus erythematosus.</article-title>
            <source>Dermatol Ther</source>
            <year>2014</year>
            <season>Mar-Apr</season>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-82</page-range>
            <pub-id pub-id-type="pmid">24703263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oren-Shabtai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Snast</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lapidoth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Noyman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mimouni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hodak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Topical and Systemic Retinoids for the Treatment of Genital Warts: A Systematic Review and Meta-Analysis.</article-title>
            <source>Dermatology</source>
            <year>2021</year>
            <volume>237</volume>
            <issue>3</issue>
            <fpage>389</fpage>
            <page-range>389-395</page-range>
            <pub-id pub-id-type="pmid">33279886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paredes-Bhushan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rezaee</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Chavez</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Isotretinoin induced urethritis: A case report &#x00026; review of the literature.</article-title>
            <source>Urol Case Rep</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>29</volume>
            <fpage>101109</fpage>
            <pub-id pub-id-type="pmid">31908966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Godley</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bradbeer</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Gellan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thin</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Cryotherapy compared with trichloroacetic acid in treating genital warts.</article-title>
            <source>Genitourin Med</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>63</volume>
            <issue>6</issue>
            <fpage>390</fpage>
            <page-range>390-2</page-range>
            <pub-id pub-id-type="pmid">3323028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fichman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hodak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Halachmi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mazor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lapidoth</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of pulsed dye laser treatment for common warts is not influenced by the causative HPV type: a prospective study.</article-title>
            <source>Lasers Med Sci</source>
            <year>2018</year>
            <month>May</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>773</fpage>
            <page-range>773-777</page-range>
            <pub-id pub-id-type="pmid">29218494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iranmanesh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khalili</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zartab</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amiri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aflatoonian</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Laser therapy in cutaneous and genital warts: A review article.</article-title>
            <source>Dermatol Ther</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>e14671</fpage>
            <pub-id pub-id-type="pmid">33314577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ba</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>XF</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CX</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>XD</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Photodynamic Therapy for Genital Warts Causes Activation of Local Immunity.</article-title>
            <source>J Cutan Med Surg</source>
            <year>2019</year>
            <season>Jul/Aug</season>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>370</fpage>
            <page-range>370-379</page-range>
            <pub-id pub-id-type="pmid">31010295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>5-Aminolevulinic photodynamic therapy versus carbon dioxide laser therapy for small genital warts: A multicenter, randomized, open-label trial.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>779</fpage>
            <page-range>779-781</page-range>
            <pub-id pub-id-type="pmid">31374308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kechichian</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Helou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sarkis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Labaki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nemr</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tomb</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The place of 5-aminolaevulinic acid-photodynamic therapy in the treatment landscape of urethral warts: A systematic review.</article-title>
            <source>Photodiagnosis Photodyn Ther</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>33</volume>
            <fpage>102204</fpage>
            <pub-id pub-id-type="pmid">33529745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Modified photodynamic therapy to minimize pain in the treatment of condylomata acuminata: A prospective, randomized, self-controlled study.</article-title>
            <source>Photodiagnosis Photodyn Ther</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>32</volume>
            <fpage>101915</fpage>
            <pub-id pub-id-type="pmid">32634656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czelusta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yen-Moore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van der Straten</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carrasco</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tyring</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>409</fpage>
            <page-range>409-32; quiz 433-6</page-range>
            <pub-id pub-id-type="pmid">10954653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nebesio</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Mirowski</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>TY</given-names>
              </name>
            </person-group>
            <article-title>Human papillomavirus: clinical significance and malignant potential.</article-title>
            <source>Int J Dermatol</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>373</fpage>
            <page-range>373-9</page-range>
            <pub-id pub-id-type="pmid">11589741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orlando</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fasolo</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Beretta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cargnel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients.</article-title>
            <source>AIDS</source>
            <year>2002</year>
            <month>Feb</month>
            <day>15</day>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>447</fpage>
            <page-range>447-50</page-range>
            <pub-id pub-id-type="pmid">11834957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaliterna</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Barisic</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Genital human papillomavirus infections.</article-title>
            <source>Front Biosci (Landmark Ed)</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>1587</fpage>
            <page-range>1587-1611</page-range>
            <pub-id pub-id-type="pmid">29293452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cusini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Micali</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lacarrubba</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Puviani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barcella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Milani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerability of nitric-zinc complex in the treatment of external genital warts and "difficult-to-treat" warts: a "proof of concept", prospective, multicentre, open study.</article-title>
            <source>G Ital Dermatol Venereol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>150</volume>
            <issue>6</issue>
            <fpage>643</fpage>
            <page-range>643-8</page-range>
            <pub-id pub-id-type="pmid">26513041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pontini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mastorino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gaspari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ramoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delmonte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Evangelista</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cusini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A Multicentre, Randomised Clinical Trial to Compare a Topical Nitrizinc<sup>&#x000ae;</sup> Complex Solution Versus Cryotherapy for the Treatment of Anogenital Warts.</article-title>
            <source>Dermatol Ther (Heidelb)</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>1063</fpage>
            <page-range>1063-1073</page-range>
            <pub-id pub-id-type="pmid">32734366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muffarrej</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khattab</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Najjar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of genital warts with cidofovir cream in a pediatric patient with Fanconi anemia.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>1234</fpage>
            <page-range>1234-1236</page-range>
            <pub-id pub-id-type="pmid">31718429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hengge</surname>
                <given-names>UR</given-names>
              </name>
              <name>
                <surname>Tietze</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of recalcitrant condyloma with topical cidofovir.</article-title>
            <source>Sex Transm Infect</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>76</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <pub-id pub-id-type="pmid">10858720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000fc;rmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Temmesfeld-Wollbr&#x000fc;ck</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grobusch</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Suttorp</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Topical cidofovir is effective in treating extensive penile condylomata acuminata.</article-title>
            <source>AIDS</source>
            <year>2000</year>
            <month>May</month>
            <day>26</day>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>1075</fpage>
            <page-range>1075-6</page-range>
            <pub-id pub-id-type="pmid">10853999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blaizot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dutkiewicz</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Guillet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pham-Ledard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beylot-Barry</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intravenous cidofovir for diffuse genital warts in the setting of multifactorial immunosuppression.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>e162</fpage>
            <page-range>e162-e163</page-range>
            <pub-id pub-id-type="pmid">27527116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22202.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Psomiadou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Iavazzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Douligeris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fotiou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prodromidou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blontzos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Karavioti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vorgias</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>An Alternative Treatment for Vaginal Cuff Wart: a Case Report.</article-title>
            <source>Acta Medica (Hradec Kralove)</source>
            <year>2020</year>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-51</page-range>
            <pub-id pub-id-type="pmid">32422116</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
